<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326183</url>
  </required_header>
  <id_info>
    <org_study_id>2006_023</org_study_id>
    <secondary_id>V251-066</secondary_id>
    <nct_id>NCT00326183</nct_id>
  </id_info>
  <brief_title>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</brief_title>
  <official_title>An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella
      [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly. Safety data
      will be collected following each vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Participants With 1 or More Serious Vaccine-Related Adverse Experiences</measure>
    <time_frame>Days 1 to 14 after any vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With 1 or More Injection-Site Adverse Experiences</measure>
    <time_frame>Days 1 to 14 after any vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Measles-Like Rash After First Vaccination</measure>
    <time_frame>Days 1 to 28 After First Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Measles-Like Rash After Second Vaccination</measure>
    <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Mumps-Like Symptoms After First Vaccination</measure>
    <time_frame>Days 1 to 28 After First Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Mumps-Like Symptoms After Second Vaccination</measure>
    <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Rubella-Like Rash After First Vaccination</measure>
    <time_frame>Days 1 to 28 After First Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Rubella-Like Rash After Second Vaccination</measure>
    <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Varicella/Zoster-Like Rash After First Vaccination</measure>
    <time_frame>Days 1 to 28 After First Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Varicella/Zoster-Like Rash After Second Vaccination</measure>
    <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Elevated Temperature (&gt;=102.2F/39.0C)</measure>
    <time_frame>Days 1 to 5 After Any Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With 1 or More Systemic Adverse Experiences</measure>
    <time_frame>Days 1 to 14 After Any Vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1800</enrollment>
  <condition>Hepatitis A</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Chickenpox</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAQTA®</intervention_name>
    <description>0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>V251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad</intervention_name>
    <description>0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Negative clinical history of hepatitis A, measles, mumps, rubella, varicella
             (chickenpox), and/or zoster

          -  No other vaccinations scheduled to be administered at the time of the first or second
             doses of VAQTA(TM) and ProQuad(TM)

        Exclusion Criteria:

          -  Previously vaccinated with any hepatitis A vaccine, measles, mumps, rubella, and/or
             varicella vaccine either alone or in any combination

          -  History of allergy to any vaccine component

          -  History of seizure disorder

          -  Immunosuppressed including congenial and acquired conditions and immunosuppressive
             therapy

          -  Known severe thrombocytopenia or any other coagulation disorder that would
             contraindicate intramuscular injections

          -  Recent (&lt;72 hours) febrile illness (&gt;100.3 degrees F [&gt;37.9 degrees C] oral
             equivalent) prior to study vaccination.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>17 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <lastchanged_date>February 19, 2009</lastchanged_date>
  <firstreceived_date>May 12, 2006</firstreceived_date>
  <firstreceived_results_date>October 21, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>18 investigators in the United States; Date of first subject visit: 26-Mar-2007.
Date of last subject visit: 14-Nov-2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: VAQTA™</title>
          <description>Hepatitis A vaccine, inactivated</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: VAQTA™ +ProQuad™</title>
          <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1453"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1 + Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1453"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Postvaccination 1 Post-safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1393"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2 + Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1301"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Postvaccination 2 Post-safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1265"/>
                <participants group_id="P2" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1253"/>
                <participants group_id="P2" count="264"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: VAQTA™</title>
          <description>Hepatitis A vaccine, inactivated</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: VAQTA™ +ProQuad™</title>
          <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1453"/>
                <measurement group_id="B2" value="347"/>
                <measurement group_id="B3" value="1800"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.3" spread="1.49"/>
                <measurement group_id="B2" value="12.5" spread="0.90"/>
                <measurement group_id="B3" value="13.2" spread="1.43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="703"/>
                <measurement group_id="B2" value="176"/>
                <measurement group_id="B3" value="879"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="750"/>
                <measurement group_id="B2" value="171"/>
                <measurement group_id="B3" value="921"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Serious Vaccine-Related Adverse Experiences</title>
        <time_frame>Days 1 to 14 after any vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1415"/>
                  <measurement group_id="O2" value="334"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With 1 or More Serious Vaccine-Related Adverse Experiences</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With 1 or More Systemic Adverse Experiences</title>
        <time_frame>Days 1 to 14 After Any Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1415"/>
                  <measurement group_id="O2" value="334"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With 1 or More Systemic Adverse Experiences</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="782"/>
                  <measurement group_id="O2" value="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With 1 or More Injection-Site Adverse Experiences</title>
        <time_frame>Days 1 to 14 after any vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1415"/>
                  <measurement group_id="O2" value="334"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With 1 or More Injection-Site Adverse Experiences</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="701"/>
                  <measurement group_id="O2" value="164"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Measles-Like Rash After First Vaccination</title>
        <time_frame>Days 1 to 28 After First Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ +ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="328"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Measles-Like Rash After First Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Measles-Like Rash After Second Vaccination</title>
        <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="263"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Measles-Like Rash After Second Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Mumps-Like Symptoms After First Vaccination</title>
        <time_frame>Days 1 to 28 After First Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="328"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Mumps-Like Symptoms After First Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Mumps-Like Symptoms After Second Vaccination</title>
        <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="263"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Mumps-Like Symptoms After Second Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Rubella-Like Rash After First Vaccination</title>
        <time_frame>Days 1 to 28 After First Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="328"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Rubella-Like Rash After First Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Rubella-Like Rash After Second Vaccination</title>
        <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="263"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Rubella-Like Rash After Second Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Varicella/Zoster-Like Rash After First Vaccination</title>
        <time_frame>Days 1 to 28 After First Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="328"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varicella/Zoster-Like Rash After First Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Varicella/Zoster-Like Rash After Second Vaccination</title>
        <time_frame>Days 1 to 28 After Second Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="263"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Varicella/Zoster-Like Rash After Second Vaccination</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Elevated Temperature (&gt;=102.2F/39.0C)</title>
        <time_frame>Days 1 to 5 After Any Vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Includes all subjects who provided body temperature follow-up data after any dose of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: VAQTA™</title>
            <description>Hepatitis A vaccine, inactivated</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: VAQTA™ +ProQuad™</title>
            <description>Hepatitis A vaccine, inactivated + measles, mumps, rubella, and varicella vaccine live</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1383"/>
                  <measurement group_id="O2" value="320"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Elevated Temperature (&gt;=102.2F/39.0C)</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck &amp; Co., Inc.</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
